Dr Donovan Tay

Dr Tay Yu Kwang Donovan is a Visiting Consultant in Endocrinology in Department of General Medicine at Sengkang General Hospital . He completed his basic specialist training and obtained the Membership of the Royal College of Physicians MRCP (UK), as well as his Master of Medicine (Singapore) in 2010. Dr Tay received further advanced specialist training in Endocrinology and was certified by the Specialists Accreditation Board of Singapore in 2013. He further undertook his fellowship and research training in Metabolic Bone Disease and Osteoporosis at the Metabolic Bone Disease Unit, Division of Endocrinology, Department of Medicine, College of Physician and Surgeons, Columbia University (New York, USA) in 2016.

Dr Tan's clinical expertise includes management of metabolic bone disease, in addition to common hormonal problems. He runs a calcium and bone clinic at Sengkang General Hospital managing patients with primary hyperparathyroidism, chronic hypoparathyroidism and osteoporosis.

MBBS: National University of Singapore 2004

MRCP (UK), M.Med (Singapore), 2010

Specialist Accreditation in Endocrinology (Singapore), 2013

Member, Endocrine and Metabolic Society of Singapore

Member, American Society of Bone and Mineral Research

Member of The Endocrine Society, USA

Member of the Pharmacy and Therapeutics committee

Member of the Expert Group for the Agency for Care Effectiveness Osteoporosis guidelines, 2018

Endocrine Trainee Day Award (ENDO 2011)

American Society Bone and Mineral Research 2015 Young Investigator Travel Grant

HMDP Fellowship: Metabolic Bone Disease and Osteoporosis, 2016

Singhealth Publish! Award 2019

1. Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, Almonte MG, Bilezikian JP, Rubin MR.
   Therapy of Hypoparathyroidism with rhPTH(1-84): A Prospective Eight Year Investigation of Efficacy and Safety.
   J Clin Endocrinol Metab. 2019 Jul 16. pii: jc.2019-00893. doi: 10.1210/jc.2019-00893.
   JIF: 5.789
   
   
2. Yeh R, Tay YD, Tabacco G, Dercle L, Kuo JH, Bandeira L, McManus C, Leung DK, Lee JA, Bilezikian JP.
   Diagnostic Performance of 4D CT and Sestamibi SPECT/CT in Localizing Parathyroid Adenomas in Primary Hyperparathyroidism.
   Radiology. 2019 Mar 3:182122. doi: 10.1148/radiol.2019182122. [Epub ahead of print]
   JIF: 7.469
   
   
3. Tay YD, Tabacco G, Cusano NE, Williams J, Omeragic B, Majeed R, Almonte MG, Rubin MR, Bilezikian JP.
   Quality of Life in Hypoparathyroidism Improves with rhPTH(1-84) Throughout 8 Years of Therapy.
   J Clin Endocrinol Metab. 2019 Feb 18. pii: jc.2018-02430. doi: 10.1210/jc.2018-02430. [Epub ahead of print]
   JIF: 5.789
   
   
4. Chandran M, McCloskey EV, Thu WPP, Logan S, Hao Y, Tay D, Ang WC, Aung TKK, Choo KS, Ali A, Yan SX, Huang XF, Liu XM, Yong EL, Lekamwasam S
   FRAX® based intervention thresholds for management of osteoporosis in Singaporean women.
   Arch Osteoporos. 2018 Nov 19;13(1):130.
   JIF: 2.382
   
   
5. Tay YKD, Starr J, Shane E
   Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
   JIF3.726
   Curr Osteoporos Rep. 2018 Aug; 16(4):519-529.doi:10.1007/s11914-018-0464-6
   
   
6. Chandran M, Tay D, Huang XF, Hao Y
   The burden of inpatient care for diabetic and non-diabetic patients with osteoporotic hip fractures-does it differ? An analysis of patients recruited into a fracture liaison service in Southeast Asia.
   Arch Osteoporos. 2018 Mar 15;13(1):27.
   JIF: 1.96
   
   
7. Tay YD, Yeh R, Kuo JH, McManus C, Lee JA, Bilezikian JP
   Pre-operative localization of abnormal parathyroid tissue by 99mTc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency.
   Endocrine. 2018 Apr;60(1):36-45. doi: 10.1007/s12020-018-1528-1.
   JIF: 3.131
   
   
8. Tay YD, Liu M, Bandeira L, Bucovsky M, Lee JA, Silverberg SJ, Walker MD.
   Occult urolithiasis in asymptomatic primary hyperparathyroidism.
   Endocr Res. 2018 Feb 5:1-10.
   JIF: 1.408
   
   
9. Donovan Tay YK, Cusano NE, Rubin MR, Williams J, Omeragic B, Bilezikian JP.
   Trabecular Bone Score in Obese and Non-obese Subjects with Primary Hyperparathyroidism Before and After Parathyroidectomy.
   J Clin Endocrinol Metab. 2018 Jan 24.
   JIF: 5.789
   
   
10. Cusano NE, Rubin MR, Silva BC, Tay YD, Williams JM, Agarwal S, Omeragic B, Guo XE, Bilezikian JP.
    Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2018 Jan 1;103(1):196-205.
    JIF: 5.789
    
    
11. Tay D, Cremers S, Bilezikian JP.
    Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.
    Br J Clin Pharmacol. 2018 Feb;84(2):252-267.
    JIF: 3.493
    
    
12. Tay YK, Khoo J, Chandran M
    Surgery or no surgery: What works best for the kidneys in primary hyperparathyroidism? A study in a multi-ethnic Asian population.
    Indian J Endocrinol Metab. 2016 Jan-Feb;20(1):55-61.
    
    
13. Chandran M, Tay D, Tan M, Hao Y, Huang XF, Khoo J, Puar TH.
    Axial BMD In Diabetic And Nondiabetic Southeast Asians With Hip Fractures: Do Race And Body Mass Index Matter?
    Endocr Pract. 2016 Jun;22(6):716-25.
    JIF: 2.811
    
    
14. Chandran M, Tay D
    The Endocrine Society of India expert group guidelines on Vitamin D deficiency in India: Recommendations for prevention and treatment: A commentary
    Indian J Endocrinol Metab. DOI:10.4103/2230-8210.194357
    
    
15. Fu WP, Lee HC, Ng CJ, Tay YK, Kau CY, Seow CJ, Siak JK, Hong CY.
    Screening for childhood obesity: international vs population-specific definitions. Which is more appropriate?
    Int J Obes Relat Metab Disord. 2003 Sep;27(9):1121-6.
    JIF: 5.487